DAY 3: Tuesday, September 23, 2025

Program subject to change.

07:00 - 18:00

Registration Open

07:15 - 18:15

Industry-Sponsored Symposia with Breakfast

08:30 - 09:30

Plenary Lecture 2

  • ADME & Delivery Strategies for Oligos
    Steve Hood, GSK, UK

10:00 - 12:00

Concurrent Symposia 5 & 6

Symposium 5: DMPK Challenges with Targeted Genetic Medicines: Exploring the New Frontiers of Oligonucleotide Therapeutics

Co-chairs: Everett Perkins, Eli Lilly, USA; Asami Toshima, Kyowa Kirin Co., Ltd., Japan

  • This symposium will review unique challenges associated with assessing and optimizing the distribution, metabolism, and PK of targeted oligonucleotide-based therapeutics.  The topics in this session will provide broad perspectives on the current and future state of oligonucleotide delivery as well as technical insight into mechanisms of metabolism and biodistribution of siRNA.

  • What are optimal PK and PK/PD properties for single and double stranded oligos?
    Ben-Filippo Krippendorff, Pierre Fabre Group, France

  • Intracellular and in Vivo Disposition of Fab– Small Interfering RNA Conjugate
    Asami Toshima, Kyowa Kirin Co, Japan

  • In vitro-in vivo assessment of siRNA metabolism
    Chris Wiethoff, Lilly, USA

  • RNAi based therapeutics and novel RNA Bioengineering technologies
    Ai-Ming Yu, Univ California, Davis, USA

Symposium 6: Impact of AI & ML in Drug Discovery & Development

Co-chairs: James Lu, Genentech, USA; Andreas Reichel, Bayer, Germany

  • This session will highlight examples of where and how artificial intelligence and, in particular, machine learning can be impactful in enhancing drug discovery and development, with talks that apply ML approaches to predicting PK and PK/PD profiles in preclinical and clinical studies, for SMOLs and BIOLs, and for the design of new modalities such as peptides, protein degraders and gene therapies.

  • Application of neural ODEs to predict PK and PK/PD profiles - case studies from drug discovery
    Filip Steinbauer, Bayer, Germany & Andreas Reichel, Bayer, Germany

  • Explainable ML workflow for exposure-response relations of large molecule oncology drugs​
    James Lu, Genentech, USA

  • ML-guided peptide drug discovery: development of GLP‑1 receptor agonists with improved drug properties
    Chris Langmead, Amgen, USA

  • Application of ML models for property prediction of targeted protein degraders
    Raquel Rodriguez-Perez, Novartis, Switzerland

12:00 - 14:30

Lunch/Exhibits/Posters Viewing/Supplier Showcase

14:30 - 15:45

2025 Awards

16:00 - 17:15

Best Poster Presentations

17:30 - 19:30

Poster Viewing